Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more
Author(s): Stephen Nicholls Added: 1 year ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,… View more
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 1 year ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4… View more
Author(s): Josep Rodés-Cabau Added: 2 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more
Author(s): Marianna Fontana Added: 8 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more
Author(s): Ahmad Masri Added: 3 months ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34… View more
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more
Author(s): P Kasi Ramanathan Added: 2 months ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P Kasi Ramanathan (Promedica Toledo Hospital, OH, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the… View more
Author(s): Paola Fioretto , Rajiv Agarwal Added: 7 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more
Research Area(s) / Expertise:

Coronary Physiology

Job title: Consultant Interventional Cardiologist and Honorary Senior Lecturer
Dr De Silva is a consultant interventional cardiologist, at St. Thomas’ Hospital and Honorary Senior Lecturer at King's College London. Dr De Silva’s clinical focus is on undertaking complex, high-risk PCI, with a particular interest in education, and methods of refining and improving quality and procedural efficiency in PCI practice. He remains dedicated to adopting and utilising new technology… View more